Goldman Sachs
VERA icon

Goldman Sachs’s Vera Therapeutics VERA Stock Holding History

Goldman Sachs’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.6M Buy
1,133,969
+13,189
+1% +$568K 0.01% 1650
2025
Q4 		$56.8M Buy
1,120,780
+362,214
+48% +$12.9M 0.01% 1412
2025
Q3 		$22M Buy
758,566
+253,945
+50% +$5.87M ﹤0.01% 2162
2025
Q2 		$11.9M Sell
504,621
-1,297
-0.3% -$29.2K ﹤0.01% 2608
2025
Q1 		$12.2M Sell
505,918
-48,811
-9% -$1.57M ﹤0.01% 2509
2024
Q4 		$23.5M Sell
554,729
-45,125
-8% -$2M ﹤0.01% 1970
2024
Q3 		$26.5M Sell
599,854
-184,714
-24% -$7.01M ﹤0.01% 1798
2024
Q2 		$28.4M Buy
784,568
+224,778
+40% +$8.92M ﹤0.01% 1584
2024
Q1 		$24.1M Sell
559,790
-89,428
-14% -$3.19M ﹤0.01% 1684
2023
Q4 		$9.98M Buy
649,218
+229,414
+55% +$2.91M ﹤0.01% 2537
2023
Q3 		$5.76M Buy
419,804
+134,311
+47% +$2.3M ﹤0.01% 2858
2023
Q2 		$4.58M Buy
+285,493
New +$2.58M ﹤0.01% 3174
2021
Q3 		– Sell
-11,747
Closed -$156K – 6534
2021
Q2 		$156K Buy
+11,747
New +$183K ﹤0.01% 5838

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs's VERA Position: Q1 2026 in Review

Goldman Sachs increased its Vera Therapeutics (VERA) stake by 1.2% in Q1 2026, buying an estimated $568K and bringing the position to 1,133,969 shares worth $45.6M. The position accounts for 0.01% of the portfolio, ranked #1650.

Goldman Sachs first reported a position in VERA in Q2 2021 and has held it in 13 quarters since. The position peaked at $56.8M in Q4 2025. 229 funds tracked by Wall St. Rank hold VERA as of Q1 2026.

  • Goldman Sachs held 1,133,969 shares of Vera Therapeutics worth $45.6M as of Q1 2026.
  • Goldman Sachs bought 13,189 Vera Therapeutics shares in Q1 2026, an estimated $568K.
  • Vera Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1650 holding.
  • Goldman Sachs first reported a position in Vera Therapeutics in Q2 2021 and has held it in 13 quarters since.
  • Goldman Sachs's Vera Therapeutics position peaked at $56.8M in Q4 2025.
  • 229 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.